Hamlet BioPharma AB (publ) (XSAT: HAMLET B)
Health Care · Biotechnology · SE
Skr6.08
+1.67% today · +26.3% 1Y
Public summary
A free snapshot of Hamlet BioPharma AB (publ), with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app Hamlet BioPharma AB (publ) (XSAT: HAMLET B) operates in the Biotechnology industry within the Health Care sector. The company is valued at $113.40M.
Over the last twelve months the share price has gained 26.3%, trading between 4.36 and 8.96.
Tweenvest scores Hamlet BioPharma AB (publ) across four factors: quality 30/100, value 80/100. Its strongest factor is value.
HAMLET B price history
Key figures
- Market cap
- $113.40M
- Revenue (TTM)
- $5.64K
- P/E
- -19.10
- EPS
- -0.30
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- Skr8.96
- 52-week low
- Skr4.36
- Avg volume (3M)
- —
- Shares outstanding
- 186.18M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Actinogen Medical LimitedASX: ACW | $117.91M | AU$0.05 | -4.26% |
| Minerva Neurosciences, Inc.NasdaqCM: NERV | $114.62M | $2.30 | -3.36% |
| Upstream Bio, Inc.NasdaqGS: UPB | $114.01M | $2.08 | -0.95% |
| Aroa Biosurgery LimitedASX: ARX | $113.78M | AU$0.49 | -2.97% |
| BNC KOREA, Inc.KOSDAQ: A256840 | $113.23M | ₩2,210.00 | -1.78% |
| GC Cell CorporationKOSDAQ: A144510 | $112.30M | ₩9,990.00 | -2.15% |
| Nykode Therapeutics ASOB: NYKD | $110.50M | Nkr2.74 | 0.00% |
| ArcticZymes Technologies ASAOB: AZT | $110.39M | Nkr21.10 | +0.48% |